

EXPRESS MAILING

EL 072 043 US

**INFORMATION  
DISCLOSURE STATEMENT**

Address to:  
Box PCT  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Attorney Docket Confirmation No.	RICE-006 Not Yet Assigned
First Named Inventor	Little
Intl. Application Number	PCT/AU00/00982
Intl. Filing Date	August 17, 2000
Priority Date Claimed	August 19, 1999
Group Art Unit	Unassigned
Examiner Name	Unassigned
Title	Drug For Treating Fractures

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefore RICE-006.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date:

February 12, 2002

By:



Alan W. Cannon  
Registration No. 34,977

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231  
F:\DOCUMENT\GUID\028\IDS - before 1st OA1.doc

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Completeness if Known</b>	
				Application Number	Unassigned
				Filing Date	Herewith
				First Named Inventor	LITTLE, DAVID G.
				Group Art Unit	Unassigned
Examiner Name	Unassigned				
Attorney Docket Number	RICE-006				
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	B1	WO	93/11786		Procter & Gamble Pharmaceuticals, Inc.	06/24/1993		
	B2	WO	94/21266		Leiras Oy	09/24/1994		
	B3	WO	95/28936		Merck & Co., Inc.	11/02/1995		
	B45	WO	96/39150		Merck & Co., Inc.	12/12/1996		
	B5	WO	96/39151		Merck & Co., Inc.	12/12/1996		
	B6	WO	98/00438		The University of Liverpool	01/08/1998		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.